To verify the clinical implications of METTL3 in glioma, we performed immunohistochemistry (IHC) staining to assess METTL3 expression in a glioma tissue microarray (TMA) cohort, with specimens collected from our institution. The gene discussed is METTL3; the disease is glioma.